A61K 38/49
Urokinase
Official title: Urokinase; Tissue plasminogen activator
A61K38/49 (Urokinase) appears on 366 US grants and 442 published applications in this corpus.
Search patents in A61K- Granted patents
- 366
- Published applications
- 442
- Assignees
- 300
- Inventors
- 813
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 3 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 10 | 0 |
| 1990 | 12 | 0 |
| 1991 | 19 | 0 |
| 1992 | 10 | 0 |
| 1993 | 11 | 0 |
| 1994 | 12 | 0 |
| 1995 | 8 | 0 |
| 1996 | 11 | 0 |
| 1997 | 11 | 0 |
| 1998 | 18 | 0 |
| 1999 | 13 | 0 |
| 2000 | 13 | 0 |
| 2001 | 11 | 3 |
| 2002 | 12 | 23 |
| 2003 | 13 | 20 |
| 2004 | 6 | 30 |
| 2005 | 5 | 18 |
| 2006 | 7 | 23 |
| 2007 | 3 | 21 |
| 2008 | 4 | 21 |
| 2009 | 1 | 14 |
| 2010 | 12 | 24 |
| 2011 | 8 | 16 |
| 2012 | 7 | 15 |
| 2013 | 11 | 15 |
| 2014 | 6 | 25 |
| 2015 | 11 | 10 |
| 2016 | 7 | 12 |
| 2017 | 8 | 10 |
| 2018 | 13 | 16 |
| 2019 | 6 | 20 |
| 2020 | 13 | 18 |
| 2021 | 12 | 18 |
| 2022 | 10 | 10 |
| 2023 | 9 | 22 |
| 2024 | 6 | 16 |
| 2025 | 3 | 16 |
| 2026 | 5 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fusion protein for targeted thrombolysis for treatment of microvascular thrombosis26 May 2026US 12,636,351 B2TargED Biopharmaceuticals B.V.
- Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase31 Mar 2026US 12,590,301 B2Thrombolytic Science, Inc.
- Method and drug for treating spinal muscular atrophy17 Mar 2026US 12,576,139 B2Talengen International Limited
- Medical use of icaritin24 Feb 2026US 12,558,343 B2Lunan Pharmaceutical Group Corporation
- Methods of treating acute coronary syndrome using 3,3′-diindolylmethane20 Jan 2026US 12,527,766 B2Boulder BioScience LLC
- Treatment of ocular injuries using microbots30 Jul 2026US 2026/0215963 A1Applied Research Associates, Inc.
- Method of preventing and/or treating tissue damage or injury18 Jun 2026US 2026/0166009 A1Morehouse School of Medicine
- Method for promoting pathological tdp-43 protein degradation, and drug18 Jun 2026US 2026/0166131 A1Talengen International Limited
- Method and drug for promoting removal of pathological proteins by ubiquitin proteasome system and autophagy lysosome system18 Jun 2026US 2026/0166132 A1Talengen International Limited
- Use of Tetramethylpyrazine Nitrone Derivatives In The Treatment of Ischemic Stroke4 Jun 2026US 2026/0151389 A1Guangzhou Magpie Pharmaceuticals Co., Ltd.
Most cited
By later US patents
- Drug delivery system making use of a hydrogel polymer coating1,007US 5,304,121 ABoston Scientific Corporation · 1994
- Drug delivery390US 5,674,192 ABoston Scientific Corporation · 1997
- Stent lining329US 5,843,089 ABoston Scientific Corporation · 1998
- Drug delivery304US 6,409,716 B1SciMed Life Systems, Inc. · 2002
- Implantable system with drug-eluting cells for on-demand local drug delivery296US 6,206,914 B1Medtronic, Inc. · 2001